Laura Sepp-Lorenzino, Ph.D., Intellia’s Chief Scientific Officer, has announced her retirement effective December 31, 2025 after more than 30 years of service in the biopharmaceutical industry and academia. Dr. Sepp-Lorenzino will transition from her role as CSO and continue as a Senior Scientific Advisor for the remainder of the year. The company also announced that Birgit Schultes, Ph.D., who has been leading Immunology and Cell Therapy since 2017, will be promoted to Executive Vice President and Chief Scientific Officer, effective January 13, 2025
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $47 from $54 at RBC Capital
- Intellia Therapeutics price target lowered to $50 from $58 at BofA
- Intellia Therapeutics reports inducement grants under Nasdaq listing rule
- Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today
- Biotech Alert: Searches spiking for these stocks today